Vegzelma Evrópusambandið - íslenska - EMA (European Medicines Agency)

vegzelma

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Æxlishemjandi lyf - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. sjá nánar í kafla 5 til að fá nánari upplýsingar varðandi húðþéttni vaxtarþáttar viðtaka 2 (her2). vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. nánari upplýsingar um her2 stöðu, sjá kafla 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Nyvepria Evrópusambandið - íslenska - EMA (European Medicines Agency)

nyvepria

pfizer europe ma eeig  - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - lækkun á lengd mæði í tengslum og tíðni hita og mæði í tengslum í fullorðinn sjúklinga með frumudrepandi lyfjameðferð fyrir illkynja (með undantekning langvarandi merg hvítblæði og myelodysplastic heilkennum).

Intrinsa Evrópusambandið - íslenska - EMA (European Medicines Agency)

intrinsa

warner chilcott uk ltd. - testósterón - kynferðisleg truflun, sálfræðileg - hormón kynlíf og stillum kynfæri - intrinsa er ætlað fyrir meðferð hypoactive kynhvöt röskun (hsdd) í tvíhliða oophorectomised og hysterectomised (skurðaðgerð völdum tíðahvörf) konur fá aðra estrógen meðferð.

Plenvu Mixtúruduft, lausn Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

plenvu mixtúruduft, lausn

norgine b.v. - macrogol 3350; natrii ascorbas inn; sodium sulfate anhydrous; acidum ascorbicum inn; natrii chloridum; kalii chloridum - mixtúruduft, lausn

Lopid Hart hylki 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lopid hart hylki 300 mg

pfizer aps - gemfibrozilum inn - hart hylki - 300 mg

Lopid Filmuhúðuð tafla 600 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lopid filmuhúðuð tafla 600 mg

pfizer aps - gemfibrozilum inn - filmuhúðuð tafla - 600 mg

Orfiril Magasýruþolin tafla 150 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril magasýruþolin tafla 150 mg

desitin arzneimittel gmbh - natrii valproas - magasýruþolin tafla - 150 mg

Orfiril Magasýruþolin tafla 600 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril magasýruþolin tafla 600 mg

desitin arzneimittel gmbh - natrii valproas - magasýruþolin tafla - 600 mg

Orfiril Mixtúra, lausn 60 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril mixtúra, lausn 60 mg/ml

desitin arzneimittel gmbh - natrii valproas - mixtúra, lausn - 60 mg/ml

Orfiril Retard Forðatafla 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril retard forðatafla 300 mg

desitin arzneimittel gmbh - natrii valproas - forðatafla - 300 mg